

Amendments to the Claims

1. (Canceled)
2. (Currently amended) ~~The A self-microemulsifying composition according to claim 4~~, comprising: (i) a drug phase comprising Etoposide, and a solvent; (ii) a co-solvent; and (iii) an emulsifying base comprising a lipid, a surfactant and a stabilizer; encapsulated in a pharmaceutically acceptable capsule shell.
3. (Currently amended) The composition according to claim 4 2, comprising (i) a drug phase comprising Etoposide and a solvent selected from the group consisting of 1-methyl-2-pyrrolidone, N-methyl-pyrrolidone, dimethyl isosorbide and dimethyl sulfoxide or a mixture thereof, (ii) a cosolvent selected from the group consisting of Diethyleneglycol-monoethylether, and Glycofurool or a mixture thereof and (iii) an emulsifying base with a HLB value ranging between 10.0 and 20.0 comprising a lipid, surfactant, and stabilizer.
4. (Currently amended) The composition according to claim 2, wherein Etoposide is in the range of from 1% to 20% weight/weight of the composition, the solvent is in the range of from 8% to 15% weight/weight of the composition, the Co-solvent is in the range of from 5% to 25% weight/weight of the composition and ~~(iii)~~ the amount of the emulsifying base is in the range from 40% to 86% weight, with respect to the total weight of the composition.
5. (Currently amended) The composition according to claim ~~3~~ 2, wherein Etoposide is in the range of from 1% to 20% weight/weight of the composition, the solvent is in the range of from 8% to 15% weight/weight of the composition, the Co-solvent is in the range of from 5% to 25% weight/weight of the composition and ~~(iii)~~ the amount of the emulsifying base is in the range from 40% to 86% weight, with respect to the total weight of the composition.

6. (Currently amended) The composition according to claim 2, wherein the solvent is ~~1-methyl-2-pyrrolidone~~ 1-methyl-2-pyrrolidone.

7. (Currently amended) The composition according to claim 3, wherein the solvent is ~~1-methyl-2-pyrrolidone~~ 1-methyl-2-pyrrolidone.

8. (Original) The composition according to claim 2, wherein the co-solvent is diethyleneglycol-mono-ethylether.

9. (Original) The composition according to claim 3, wherein the co-solvent is diethyleneglycol-mono-ethylether.

~~44~~ 10. (Currently amended) The composition according to claim 2, comprising (i) a drug phase comprising Etoposide and a solvent selected from N-methyl-pyrrolidone, or Dimethylisosorbide, (ii) a cosolvent selected from Diethyleneglycol-monoethylether, and Glycofural and (iii) an emulsifying phase comprising a lipid~~(s)~~ selected from the group consisting of Lauroyl macrogol-32-glycerides, Linoleoyl macrogol-6-glycerides, Caprylocaproyl macrogol-7 glycerides, Medium chain triglyceride oils, propylene glycol caprylate/caprate, propylene glycol derivatives of fatty acids, glyceryl esters of fatty acids, glycerol esters of fatty acids, and Fish lipid oils or a combination thereof; a surfactant~~(s)~~ selected from the group of Polysorbates, Sorbitan esters, polyethylene-propyleneglycol-copolymers, Polyoxyethylene castor oil derivatives, Caprylocaproyl Macrogol-8 glycerides, Propylene glycol laureate, Polyglyceryl-6-dioleate, Propylene glycol monocaprylates, Sodium lauryl sulphate, ~~Docosate~~ Docosate sodium, or bile salts or a combination thereof, and a stabilizer~~(s)~~ selected from the group consisting of antioxidants, carboxylic acids, and chelating agents or a combination thereof.

~~42~~ 11. (Currently amended) The composition of Etoposide according to claim 2 comprising Etoposide, N-methyl-pyrrolidone, Diethyleneglycolmonoethylether, medium chain triglyceride oils, Caprylocaproyl macrogol-7 glycerides and Lauroyl

macrogol-32-glycerides, Polysorbates, Sorbitan esters, polyethylene-propyleneglycol-copolymers, Polyoxyethylene castor oil derivatives, Caprylocaproyl Macrogol-8 glycerides, Propylene glycol laureate, Polyglyceryl-6-dioleate, Propyleneglycol monocaprylates, propylene glycol derivatives of fatty acids, and glyceryl esters of fatty acids, Citric acid and Vitamin-E, ~~and encapsulated in a pharmaceutically acceptable shell.~~

12. (Original) The composition according to claim 2 comprising etoposide, N-methyl-pyrrolidone, diethyleneglycol monoethyl ether, polyoxyl 35 Castor oil, polysorbate-20, citric acid and d-alpha tocopherol.

13. (Canceled)